PTC Therapeutics Inc

Most Recent

  • uploads///headache _
    Company & Industry Overviews

    Analyzing PTC Therapeutics’ Performance in September

    On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.

    By Daniel Collins
  • uploads///tablets _
    Earnings Report

    Biogen Stock Trending Higher on Strong Q2 2018 Results

    Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. Here’s what you need to know.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    PTC Therapeutics to Acquire Agilis Biotherapeutics

    On July 19, PTC Therapeutics (PTCT) agreed to acquire Agilis Biotherapeutics. The acquisition is expected to close during Q3 2018.

    By Daniel Collins
  • uploads///Firefish
    Company & Industry Overviews

    Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?

    In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    Why Investors Are in a Frenzy over Sarepta Stock in June

    On June 19, Sarepta Therapeutics (SRPT) announced positive preliminary results from its phase one part 2a gene therapy micro dystrophin trial.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Yesterday, PTC Therapeutics (PTCT) registered a stock price rise of ~24.6% on the positive data the company presented along with partner Roche (RHHBY) for their SMA (spinal muscular atrophy) drug risdiplam.

    By Sarah Collins
  • uploads///dECLINES
    Company & Industry Overviews

    S&P 500’s Top Losses: Why Biogen Declined

    Biogen, which is an American multinational biotechnology company, was the S&P 500’s top loss on June 18.

    By Val Kensington
  • uploads///VX
    Company & Industry Overviews

    Vertex Presented Successful Results for Cystic Fibrosis Treatment

    Vertex Pharmaceuticals’ peers that are actively conducting research and development for CF drugs include Pfizer (PFE), PTC Therapeutics (PTCT), Proteostasis Therapeutics (PTI), Novartis, and Roche.

    By Daniel Collins
  • uploads///pipeline
    Company & Industry Overviews

    Inside Vertex Pharmaceuticals’ Clinical Pipeline

    In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Celldex Rose on Phase 2 Melanoma Data

    On June 6, 2016, Celldex Therapeutics (CLDX) was one of the top gainers in the small-cap segment of IBB. CLDX stock rose after the company announced its Phase 2 melanoma data.

    By Peter Neil
  • uploads///Exon skipping
    Earnings Report

    BioMarin Has Suffered from Kyndrisa’s Rejection

    The recent fall in BioMarin’s stock price is due to the rejection of its drug Kyndrisa, indicated for Duchenne muscular dystrophy.

    By Jillian Dabney
  • uploads///Graph Geography
    Company & Industry Overviews

    R&D Failure Is the Principal Risk Faced by BioMarin

    The biotechnology industry operates in a dynamic environment embedded with a high-risk business model. The principal risk faced by the industry is R&D failure.

    By Jillian Dabney
  • uploads///Graph pipeline
    Company & Industry Overviews

    BioMarin’s Pipeline for Duchenne Muscular Dystrophy

    There are four drugs in the pipeline targeting Duchenne muscular dystrophy. The company holds Kyndrisa, BMN044, BMN045, and BMN053 for the indication of DMD.

    By Jillian Dabney
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    XBI Rises in Contrast to a Flat Market

    XBI closed at $68.65 on November 17, 2015. Out of XBI’s 101 holdings, 70 stocks ended with positive returns, while 31 stocks ended in the red.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Ultragenyx: A Top Loser in the Biotechnology Subgroup

    Ultragenyx Pharmaceutical (RARE) fell by 8.2% due to profit-booking. It had a high trading volume of ~700,000 shares. The stock closed at $86.99.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.